OraSure (OSUR) Q2 2026 Earnings Call Transcript
OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.
How this was made
The 30-second read
Why it matters
The most market-relevant items are (1) Q3 revenue guidance ($29.5M-$32.5M), (2) margin improvement (GAAP gross margin 43.5%), and (3) a specific regulatory expectation change: no longer expecting FDA clearance and US launch for IntelliQ CT/NG in 2026 after withdrawing the submission.
Market read
This is a guidance-and-regulatory-timeline update anchored by Q2 financials and explicit Q3 revenue range, with a clear IntelliQ CT/NG 2026 delay risk.
What to watch
Cash flow was negative in Q2 and G&A included nonrecurring legal costs; traders may need to watch whether Q3 expense normalization and product launch contributions translate into improved operating cash flow.
Background
OraSure’s Q2 2026 call frames 2026 as a transition year from restructuring to focused growth, with multiple FDA milestones and one notable regulatory timeline extension.
Ticker impact
OraSure reported Q2 2026 revenue of $30.6M, guided Q3 revenue to $29.5M-$32.5M, and said it no longer expects FDA clearance for IntelliQ CT/NG in 2026.
Near-term volatility likely, with downside risk from the IntelliQ CT/NG 2026 delay offset by margin improvement and new product/regulatory wins.
The article contains multiple fresh, decision-relevant datapoints: Q2 financials, explicit Q3 revenue guidance, and a new FDA timeline expectation change for a specific test. Offsetting positives include Colli-Pee clearance and OraQuick Ebola EUA, but the regulatory delay is a direct risk to future revenue timing.
Market effects
Signals continued progress in decentralized diagnostics (EUA/clearance) but highlights regulatory friction risk for molecular self-test platforms.
Limited direct regional read-through; UK draft guidance and US FDA actions are the main geographic signals.
UK NICE draft guidance and international channel integration (SickleSCAN) suggest broader adoption pathways, but regulatory timelines remain a key constraint.
Counterpoint
The IntelliQ CT/NG 2026 delay may be more about timing than fundamental viability, while Colli-Pee and OraQuick Ebola approvals could accelerate near-term revenue enough to offset the setback.
Key entities
- companyOraSure Technologies, Inc.
Reported Q2 2026 results, issued Q3 revenue guidance, and updated FDA timeline expectations for IntelliQ CT/NG.
- productIntelliQ CT/NG
Rapid molecular self-test platform whose FDA submission was withdrawn, extending the expected clearance timeline beyond 2026.
- productColli-Pee urine collection kit
Received FDA clearance, enabling at-home self-collection for STI testing on Roche cobas.
- productOraQuick Ebola 2.0
Received FDA Emergency Use Authorization, developed with BARDA, detecting all four known Ebola species.
- regulatorNICE (UK) draft guidance
Draft guidance recommending Ziwig Endotest using OraSure OMNIgene saliva collection technology.
